FibroGen, Inc (NASDAQ:FGEN) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Monday.
Several other research firms also recently commented on FGEN. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a report on Friday, July 21st. Jefferies Group LLC began coverage on shares of FibroGen in a report on Monday, July 10th. They issued a “buy” rating and a $50.00 price objective on the stock. Citigroup Inc. reiterated a “buy” rating and issued a $48.00 price objective on shares of FibroGen in a report on Monday, June 26th. Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 price objective (up from $32.00) on shares of FibroGen in a report on Thursday, June 22nd. Finally, William Blair reiterated an “outperform” rating on shares of FibroGen in a report on Monday, June 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $40.57.
Shares of FibroGen (FGEN) opened at 33.80 on Monday. The company’s market capitalization is $2.36 billion. The firm has a 50-day moving average of $32.84 and a 200-day moving average of $27.51. FibroGen has a one year low of $15.60 and a one year high of $35.85.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. The firm had revenue of $26.89 million for the quarter, compared to the consensus estimate of $26.02 million. Equities research analysts expect that FibroGen will post ($1.85) EPS for the current fiscal year.
In other news, Director Toshinari Tamura sold 30,000 shares of the business’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $28.89, for a total value of $866,700.00. Following the completion of the sale, the director now owns 60,000 shares of the company’s stock, valued at $1,733,400. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider K Peony Yu sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $26.38, for a total transaction of $131,900.00. Following the completion of the sale, the insider now directly owns 227,346 shares of the company’s stock, valued at approximately $5,997,387.48. The disclosure for this sale can be found here. In the last three months, insiders sold 371,628 shares of company stock valued at $11,349,624. 14.90% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in FGEN. Ameritas Investment Partners Inc. acquired a new stake in shares of FibroGen during the first quarter worth about $111,000. Airain ltd acquired a new stake in shares of FibroGen during the first quarter worth about $236,000. Parametric Portfolio Associates LLC acquired a new stake in shares of FibroGen during the first quarter worth about $249,000. Great West Life Assurance Co. Can boosted its stake in shares of FibroGen by 107.0% in the second quarter. Great West Life Assurance Co. Can now owns 8,694 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 4,494 shares during the last quarter. Finally, UBS Asset Management Americas Inc. acquired a new stake in shares of FibroGen during the first quarter worth about $288,000. 44.06% of the stock is owned by institutional investors.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
